Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
10.1017/S0031182009991600 34 van der WerfM
It takes 30 seconds total and costs nothing
The location and size of River Park provide a unique opportunity to solve and address some of Austins biggest challenges such as housing supply, affordability, connectivity and mobility all on an urban infill site within five minutes of downtown, Michael Piano, director of development at Presidium, says in a December 21 release.
